KO Cancer Act

This bill boosts cancer research and tackles cancer drug shortages. It notes that cancer causes nearly 1 out of every 4 deaths in the U.S. and says more awareness and research can save lives. It adds extra money to the National Cancer Institute for research each year from 2026 through 2030—an amount equal to 25% of what the Institute received in 2022, on top of its regular funding.

It also tells the Department of Health and Human Services, through the Food and Drug Administration, to study why cancer medicines run short and to report back within one year with solutions. The study must look at money issues, supply chain problems, delays in developing and approving drugs, and the lack of generic and biosimilar options.

• Who is affected: People with cancer and their families; the National Cancer Institute; HHS and FDA.
• What changes: Extra research funding for the National Cancer Institute; a required study and recommendations to fix cancer drug shortages.
• When: Funding runs from 2026 to 2030; the drug shortage report is due within one year after the bill becomes law.